AI assistant
Editas Medicine, Inc. — Director's Dealing 2021
Mar 4, 2021
33260_dirs_2021-03-04_762683f3-7fb3-430f-96ba-85e3349c1537.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2021-03-02
Reporting Person: ROBERTSON MICHELLE (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-02 | Common Stock | A | 10303 | — | Acquired | 28735 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-02 | Stock Option (right to buy) | $45.69 | A | 32197 | Acquired | 2031-03-01 | Common Stock (32197) | Direct |
Footnotes
F1: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2022 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2025.
F2: This option was granted on March 2, 2021 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2021 through March 2, 2025.